Responses
Psoriatic arthritis
Original article
Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial
Compose a Response to This Article
Other responses
No responses have been published for this article.